Skip to main content
Equibles
IKT logo

IKT · Inhibikase Therapeutics, Inc.

Track IKT — free

Use IKT with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about IKT

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$2.41 +0.00 (+0.00%) At close · Aug 14
Market Cap
$336.28M
Shares
139.54M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.41 Open$2.39 Day$2.37–2.44 52W close$1.41–2.47 Avg vol 30d862K Short int19.1M · 13.7% float · 21.5d Short vol56% Last earningsAug 11, 2026 DataJun 2023–Aug 2026 Filing10-Q · Aug 11

Raw chart and full-history price indicators begin at the captured split on Jun 30, 2023; bars on opposite sides are not compared.

Up next

Next earnings call
Nov 11, 2026 Est · unconfirmed · in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 11, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 14.3 · calm Equity put/call 0.52
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +33%
above
Price vs 50-day avg +17%
above
RSI (14) 62
neutral
MACD trend Negative
52-week position 94%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +14%
trailing
6-month return +34%
trailing
YTD return +18%
this year
Relative strength +20%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Flat
0% holders QoQ · +19 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
13.71% of float · ▲ +4.8% MoM · 21.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
104 holders — near 3-yr high, broad support
Squeeze score 85
high risk · 0–100
Fundamentals
Fair
Revenue growth −100%
Y/Y
EPS growth +58%
Y/Y
Free cash flow $-27.8M
Balance sheet $178.4M
net cash
Quant / Vol
risk profile
Very High
Volatility 65%
annualized · 1-yr
Max drawdown −27%
past year
ATR 5.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+33% Bullish
Price vs 50-day avg
+17% Bullish
RSI (14)
62 Neutral
MACD trend
Negative Bearish
52-week position
94% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Flat
0% holders QoQ · +19 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
13.71% of float · ▲ +4.8% MoM · 21.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
104 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $2 · 94% Range high $2
vs 200-day avg +33% vs 50-day avg +17%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
IKT
Inhibikase Therapeutics, Inc.
this stock
$336.28M +17.6% -100.0% — 13.7%
ONC
BeOne Medicines Ltd.
 $513.62B +14.4% +22179.2% 789.7 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $128.19B +11.6% +46.2% 29.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $82.72B +4.1% +20.8% 19.9 3.3%
ARGX
Argenx SE
 $52.94B +1.2% — — 2.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
104
% held
85.7%
Net QoQ
+5.6M sh
Top holder
Sands Capital Life Scienc…
Held Float
View
Held by Funds
Fund positions
84
View
Short & Settlement
Short Interest Rising
Shares short
19.1M
Days to cover
21.5d
Change
+874.3K sh
View
Short Volume
Short vol %
56%
As of
Aug 14, 2026
Short Total
View
Fails to Deliver
FTD shares
8.4K
Value
$17.0K
As of
Jul 10, 2026
View
Off-Exchange
Off-exchange %
35.5%
Week of
Jul 6, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-48.3M
EPS diluted
$-0.49
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 11, 2026
This year
12
View
Exempt Offerings
Offering
$8.0M
Filed
Jun 4, 2024
View
Earnings & Events
Earnings Calls
Last call
Aug 11, 2026
View

Performance

Raw-price comparisons begin at the captured split on Jun 30, 2023; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
IKT -2.4% +14.2% +33.9% +10.6% +17.6%
SPY +0.4% +4.5% +13.8% +3.9% +13.9%
vs SPY -2.8% +9.8% +20.1% +6.6% +3.7%
Key facts CIK 1750149 CUSIP 45719W205 13F (30d) 106 filings 104 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)